Influence of Clonidine on Thrombozytes of Blood of Patients Under Anticoagulation Therapy With ASS and Clopidogrel
|ClinicalTrials.gov Identifier: NCT01314235|
Recruitment Status : Unknown
Verified March 2011 by Goethe University.
Recruitment status was: Recruiting
First Posted : March 14, 2011
Last Update Posted : March 14, 2011
Clonidin works as a presynaptic agonist of alpha-sympathomimetic receptors of the brain but also in many other tissues. It is part of balanced anesthesia in general anesthesiology as well as a sedastive agent in intensive care units, but also serves as a third-line agent in many psychiatric diseases including ADHD, schizophrenia and PTSD.
The investigators want to show whether clonidin has an procoagulatoric effect on thrombozytes of patients under double anticoagulaotirc treatment with ASS and clopidogrel. The investigators will use a flowcytometric assay to determine activation of thrombozytes when they come into contact with clonidine in vitro as well as Multiplate analyses to determine activation of thrombozytes, either thrombin.induced aggregation, ADP-induced aggregation or arachidonic acid-induced aggregation of thrombozytes.
|Condition or disease|
|Study Type :||Observational|
|Official Title:||The Influence of Clonidine on the Thrombozytes of Patients Under Double Anticagulation With ASS and Clopidogrel - an in Vitro Study|
|Study Start Date :||October 2010|
- Numbers of participants with an activated area under the curve in ASPI test [ Time Frame: 30 minutes ]Blood of patients under ASS and clopidogrel will show an activated platelet aggregation due to titrated clonidine in ASPI test, i.e. an activated area under the curve in Multiplate analysis.
- Numbers of participants with an activated area under the curve in TRAP test and ADP test [ Time Frame: 30 minutes ]Blood of patients under ASS and clopidogrel will show an activated platelet aggregation due to titrated clonidine in TRAP test and ADP test, i.e. an activated area under the curve in Multiplate analysis.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01314235
|Frankfurt, Hesse, Germany, 60590|
|Contact: Philipp Schmidt, M.D. email@example.com|